‘Can I have some, please?’: has Trump opened the door to a psychedelic future?
Summary
President Donald Trump signed an executive order to speed up research on psychedelic drugs and improve access to them. The order directs the FDA to quickly review certain psychedelic drug candidates and supports the use of some psychedelics under “right to try” laws for seriously ill patients. This marks a change in the government's approach to these drugs, which have been illegal for decades.Key Facts
- President Trump signed an order to accelerate psychedelic drug research and increase access.
- The FDA will fast-track reviews of three psychedelic drugs: psilocybin for depression and MDMA for PTSD.
- The order includes making ibogaine available under “right to try” laws, which help terminally ill patients try experimental treatments.
- This move could cause conflict with the DEA because schedule I drugs like psychedelics are usually excluded from “right to try.”
- The Department of Health and Human Services announced $139 million to support new behavioral health therapies, including psychedelics.
- The order aims to boost participation in clinical studies, especially among military veterans.
- Psychedelic drugs have been illegal at the federal level since 1970 under the Controlled Substances Act.
- Rescheduling these drugs to allow medical use will be part of the process following FDA approvals, according to the order.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.